adamantane has been researched along with Adverse Drug Event in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahal, UP; Gilbert, AM; Obach, RS | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Bialek, C; Brath, H; Gingl, E; Prager, R; Ratzinger, M; Resl, M | 1 |
| Dangi-Garimella, S | 1 |
| Goodman, M; Penman, J; Thurston, H | 1 |
| Apter, A; Bhullar, H; Carbonari, DM; Cardillo, S; Esposito, DB; Fortier, K; Freeman, CP; Haynes, K; Hennessy, S; Holick, CN; Horne, LN; Kimmel, SE; Lo Re, V; Margolis, D; Ming, EE; Razzaghi, H; Reddy, KR; Reese, PP; Roy, J; Strom, BL; Van Staa, TP; Wood Ives, J | 1 |
2 trial(s) available for adamantane and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.
Topics: Adamantane; Administration, Oral; Austria; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prevalence; Pyrrolidines; Treatment Outcome; Vildagliptin | 2015 |
Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2009 |
4 other study(ies) available for adamantane and Adverse Drug Event
| Article | Year |
|---|---|
Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs.
Topics: Adamantane; Aspirin; Carbon Radioisotopes; Cells, Cultured; Drug-Related Side Effects and Adverse Reactions; Glutathione; Half-Life; Hepatocytes; Humans; Lactones; Lysine; Nitriles; Orlistat; Pharmaceutical Preparations; Pyrrolidines; Tritium; Vildagliptin | 2013 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2014 |
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
Topics: Adamantane; Adverse Drug Reaction Reporting Systems; Algorithms; Cohort Studies; Consumer Product Safety; Databases, Factual; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Epidemiologic Research Design; Humans; Pharmacoepidemiology; Retrospective Studies; United Kingdom | 2012 |